LU85058A1 - Comprimes pharmaceutiques a liberation prolongee,leur preparation et leur utilisation - Google Patents

Comprimes pharmaceutiques a liberation prolongee,leur preparation et leur utilisation Download PDF

Info

Publication number: LU85058A1
Authority: LU; Luxembourg
Prior art keywords: tablet; tablet according; derivatives; active principle; mixture
Prior art date: 1983-10-24

Application number

LU85058A

Other languages

English (en)

French (fr)

Inventor

Philippe Baudier

Arthur Marie Deboeck

Original Assignee

Pharlyse

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1983-10-24

Filing date

1983-10-24

Publication date

1985-06-19

1983-10-24 Application filed by Pharlyse filed Critical Pharlyse

1983-10-24 Priority to LU85058A priority Critical patent/LU85058A1/fr

1984-10-12 Priority to EP84201468A priority patent/EP0142877A3/de

1985-06-19 Publication of LU85058A1 publication Critical patent/LU85058A1/fr

Links

238000013268 sustained release Methods 0.000 title claims description 5
239000012730 sustained-release form Substances 0.000 title claims description 5
238000002360 preparation method Methods 0.000 title description 4
239000000126 substance Substances 0.000 claims description 19
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 14
239000011159 matrix material Substances 0.000 claims description 12
229920002678 cellulose Polymers 0.000 claims description 10
239000001913 cellulose Substances 0.000 claims description 10
239000000203 mixture Substances 0.000 claims description 10
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 8
239000008101 lactose Substances 0.000 claims description 8
235000019359 magnesium stearate Nutrition 0.000 claims description 7
229920000058 polyacrylate Polymers 0.000 claims description 7
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
239000008187 granular material Substances 0.000 claims description 6
238000000034 method Methods 0.000 claims description 5
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 4
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 4
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 4
229920003134 Eudragit® polymer Polymers 0.000 claims description 4
229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 4
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 4
235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 4
239000000546 pharmaceutical excipient Substances 0.000 claims description 4
239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 3
229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 3
229920001249 ethyl cellulose Polymers 0.000 claims description 3
235000019325 ethyl cellulose Nutrition 0.000 claims description 3
239000012634 fragment Substances 0.000 claims description 3
235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 3
TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 claims description 3
RPZANUYHRMRTTE-UHFFFAOYSA-N 2,3,4-trimethoxy-6-(methoxymethyl)-5-[3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxyoxane;1-[[3,4,5-tris(2-hydroxybutoxy)-6-[4,5,6-tris(2-hydroxybutoxy)-2-(2-hydroxybutoxymethyl)oxan-3-yl]oxyoxan-2-yl]methoxy]butan-2-ol Chemical compound COC1C(OC)C(OC)C(COC)OC1OC1C(OC)C(OC)C(OC)OC1COC.CCC(O)COC1C(OCC(O)CC)C(OCC(O)CC)C(COCC(O)CC)OC1OC1C(OCC(O)CC)C(OCC(O)CC)C(OCC(O)CC)OC1COCC(O)CC RPZANUYHRMRTTE-UHFFFAOYSA-N 0.000 claims description 2
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 2
229940127291 Calcium channel antagonist Drugs 0.000 claims description 2
229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 2
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
239000001856 Ethyl cellulose Substances 0.000 claims description 2
VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 claims description 2
239000005662 Paraffin oil Substances 0.000 claims description 2
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
229930006000 Sucrose Natural products 0.000 claims description 2
230000003556 anti-epileptic effect Effects 0.000 claims description 2
239000002260 anti-inflammatory agent Substances 0.000 claims description 2
229940121363 anti-inflammatory agent Drugs 0.000 claims description 2
230000003110 anti-inflammatory effect Effects 0.000 claims description 2
239000001961 anticonvulsive agent Substances 0.000 claims description 2
239000000935 antidepressant agent Substances 0.000 claims description 2
229940005513 antidepressants Drugs 0.000 claims description 2
229960003965 antiepileptics Drugs 0.000 claims description 2
235000010323 ascorbic acid Nutrition 0.000 claims description 2
229960005070 ascorbic acid Drugs 0.000 claims description 2
239000011668 ascorbic acid Substances 0.000 claims description 2
229940049706 benzodiazepine Drugs 0.000 claims description 2
150000001557 benzodiazepines Chemical class 0.000 claims description 2
239000002876 beta blocker Substances 0.000 claims description 2
229940097320 beta blocking agent Drugs 0.000 claims description 2
239000011575 calcium Substances 0.000 claims description 2
229910052791 calcium Inorganic materials 0.000 claims description 2
235000001465 calcium Nutrition 0.000 claims description 2
239000000480 calcium channel blocker Substances 0.000 claims description 2
239000001506 calcium phosphate Substances 0.000 claims description 2
229910000389 calcium phosphate Inorganic materials 0.000 claims description 2
235000011010 calcium phosphates Nutrition 0.000 claims description 2
OCHFNTLZOZPXFE-JEDNCBNOSA-N carbonic acid;(2s)-2,6-diaminohexanoic acid Chemical compound OC(O)=O.NCCCC[C@H](N)C(O)=O OCHFNTLZOZPXFE-JEDNCBNOSA-N 0.000 claims description 2
239000001768 carboxy methyl cellulose Substances 0.000 claims description 2
235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 2
239000008112 carboxymethyl-cellulose Substances 0.000 claims description 2
239000002934 diuretic Substances 0.000 claims description 2
229940030606 diuretics Drugs 0.000 claims description 2
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 claims description 2
238000013265 extended release Methods 0.000 claims description 2
238000005194 fractionation Methods 0.000 claims description 2
239000001863 hydroxypropyl cellulose Substances 0.000 claims description 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims description 2
-1 pain relievers Substances 0.000 claims description 2
229920000642 polymer Polymers 0.000 claims description 2
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 claims description 2
150000003839 salts Chemical class 0.000 claims description 2
229920002545 silicone oil Polymers 0.000 claims description 2
229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 2
235000017557 sodium bicarbonate Nutrition 0.000 claims description 2
235000019333 sodium laurylsulphate Nutrition 0.000 claims description 2
235000010199 sorbic acid Nutrition 0.000 claims description 2
229940075582 sorbic acid Drugs 0.000 claims description 2
239000004334 sorbic acid Substances 0.000 claims description 2
239000000600 sorbitol Substances 0.000 claims description 2
239000005720 sucrose Substances 0.000 claims description 2
229930003799 tocopherol Natural products 0.000 claims description 2
239000011732 tocopherol Substances 0.000 claims description 2
235000019149 tocopherols Nutrition 0.000 claims description 2
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 2
QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 claims description 2
241000928106 Alain Species 0.000 claims 1
239000002253 acid Substances 0.000 claims 1
239000003795 chemical substances by application Substances 0.000 claims 1
229940088597 hormone Drugs 0.000 claims 1
239000005556 hormone Substances 0.000 claims 1
229940124641 pain reliever Drugs 0.000 claims 1
ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 12
239000003814 drug Substances 0.000 description 9
229940079593 drug Drugs 0.000 description 8
239000004480 active ingredient Substances 0.000 description 6
229960000278 theophylline Drugs 0.000 description 6
229920003148 Eudragit® E polymer Polymers 0.000 description 4
229920003091 Methocel™ Polymers 0.000 description 4
NEDGUIRITORSKL-UHFFFAOYSA-N butyl 2-methylprop-2-enoate;2-(dimethylamino)ethyl 2-methylprop-2-enoate;methyl 2-methylprop-2-enoate Chemical compound COC(=O)C(C)=C.CCCCOC(=O)C(C)=C.CN(C)CCOC(=O)C(C)=C NEDGUIRITORSKL-UHFFFAOYSA-N 0.000 description 4
230000001105 regulatory effect Effects 0.000 description 3
SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 2
229920003152 Eudragit® RS polymer Polymers 0.000 description 2
239000011248 coating agent Substances 0.000 description 2
238000000576 coating method Methods 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
230000000694 effects Effects 0.000 description 2
FSXVSUSRJXIJHB-UHFFFAOYSA-M ethyl prop-2-enoate;methyl 2-methylprop-2-enoate;trimethyl-[2-(2-methylprop-2-enoyloxy)ethyl]azanium;chloride Chemical compound [Cl-].CCOC(=O)C=C.COC(=O)C(C)=C.CC(=C)C(=O)OCC[N+](C)(C)C FSXVSUSRJXIJHB-UHFFFAOYSA-M 0.000 description 2
238000013467 fragmentation Methods 0.000 description 2
238000006062 fragmentation reaction Methods 0.000 description 2
IQSHMXAZFHORGY-UHFFFAOYSA-N methyl prop-2-enoate;2-methylprop-2-enoic acid Chemical compound COC(=O)C=C.CC(=C)C(O)=O IQSHMXAZFHORGY-UHFFFAOYSA-N 0.000 description 2
229960001722 verapamil Drugs 0.000 description 2
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
229920003139 Eudragit® L 100 Polymers 0.000 description 1
229920003151 Eudragit® RL polymer Polymers 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
230000009471 action Effects 0.000 description 1
229940035676 analgesics Drugs 0.000 description 1
239000000730 antalgic agent Substances 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
239000002216 antistatic agent Substances 0.000 description 1
208000006673 asthma Diseases 0.000 description 1
230000036765 blood level Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
230000008859 change Effects 0.000 description 1
235000015165 citric acid Nutrition 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
230000001079 digestive effect Effects 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
239000012738 dissolution medium Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
230000003628 erosive effect Effects 0.000 description 1
239000012530 fluid Substances 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
230000003054 hormonal effect Effects 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
238000005470 impregnation Methods 0.000 description 1
230000001788 irregular Effects 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
238000002483 medication Methods 0.000 description 1
239000002609 medium Substances 0.000 description 1
DNKKLDKIFMDAPT-UHFFFAOYSA-N n,n-dimethylmethanamine;2-methylprop-2-enoic acid Chemical compound CN(C)C.CC(=C)C(O)=O.CC(=C)C(O)=O DNKKLDKIFMDAPT-UHFFFAOYSA-N 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
239000003002 pH adjusting agent Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
230000004962 physiological condition Effects 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
OVARTBFNCCXQKS-UHFFFAOYSA-N propan-2-one;hydrate Chemical compound O.CC(C)=O OVARTBFNCCXQKS-UHFFFAOYSA-N 0.000 description 1
230000009467 reduction Effects 0.000 description 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
231100001274 therapeutic index Toxicity 0.000 description 1
231100000816 toxic dose Toxicity 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Preparation (AREA)

LU85058A 1983-10-24 1983-10-24 Comprimes pharmaceutiques a liberation prolongee,leur preparation et leur utilisation LU85058A1 (fr)

Priority Applications (2)

Application Number	Priority Date	Filing Date	Title
LU85058A LU85058A1 (fr)	1983-10-24	1983-10-24	Comprimes pharmaceutiques a liberation prolongee,leur preparation et leur utilisation
EP84201468A EP0142877A3 (de)	1983-10-24	1984-10-12	Arzneimitteltabletten mit verlängerter Wirkung, deren Herstellung sowie deren Verwendung

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
LU85058		1983-10-24
LU85058A LU85058A1 (fr)	1983-10-24	1983-10-24	Comprimes pharmaceutiques a liberation prolongee,leur preparation et leur utilisation

Publications (1)

Publication Number	Publication Date
LU85058A1 true LU85058A1 (fr)	1985-06-19

Family

ID=19730159

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LU85058A LU85058A1 (fr)	1983-10-24	1983-10-24	Comprimes pharmaceutiques a liberation prolongee,leur preparation et leur utilisation

Country Status (2)

Country	Link
EP (1)	EP0142877A3 (de)
LU (1)	LU85058A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3681348D1 (de) *	1985-06-11	1991-10-17	Teijin Ltd	Oral-arzneizubereitung mit retardwirkung.
LU86077A1 (fr) *	1985-09-18	1987-04-02	Pharlyse Sa	Nouvelles formes galeniques du verapamil,leur fabrication et medicaments contenant ces nouvelles formes galeniques
LU86099A1 (fr) *	1985-09-30	1987-04-02	Pharlyse	Formes galeniques a liberation prolongee du verapamil,leur fabrication et medicaments les contenant
CA1316110C (en) *	1987-02-27	1993-04-13	Eli Lilly And Company	Sustained release matrix formulations
US4968508A (en) *	1987-02-27	1990-11-06	Eli Lilly And Company	Sustained release matrix
GB8707416D0 (en) *	1987-03-27	1987-04-29	Wellcome Found	Pharmaceutical formulations
IT1222414B (it) *	1987-07-31	1990-09-05	Chiesi Farma Spa	Composizioni farmaceutiche contenenti trapidil,loro procedimento di preparazione e relaticvo impiego terapeutico
JPH0273011A (ja) *	1988-07-28	1990-03-13	Warner Lambert Co	医薬投与剤型製造用のセルロースおよびアクリル系重合体の水性重合体分散体およびその投与剤型
DE4021678C2 (de) *	1990-07-07	1994-07-07	Merz & Co Gmbh & Co	Verfahren zur Herstellung klein dimensionierter Formkörper mit hohem Etofibrat-Gehalt und kontrollierter Wirkstoff-Freisetzung, deren Verwendung und daraus bestehende oral verabreichbare Applikationsformen
IT1250654B (it) *	1991-07-08	1995-04-21	Farcon Ag	Metodo per la preparazione di forme farmaceutiche orali a rilascio prolungato contenenti sostanze attive a solubilita' dipendente dal valore di ph.
DE4138513A1 (de) *	1991-11-23	1993-05-27	Basf Ag	Feste pharmazeutische retardform
DE4220782A1 (de) *	1992-06-25	1994-01-05	Basf Ag	Verfahren zur Herstellung von festen pharmazeutischen Retardformen
JP3707798B2 (ja) *	1996-05-13	2005-10-19	ノバルティス・コンシューマー・ヘルス・ソシエテ・アノニム	口内薬剤輸送系
US6210710B1 (en) *	1997-04-28	2001-04-03	Hercules Incorporated	Sustained release polymer blend for pharmaceutical applications
US20090011007A1 (en)	2006-02-03	2009-01-08	Evonik Roehm Gmbh	Pharmaceutical Compositions Containing Mixtures of Polymers and Active Agents Poorly Soluble in Water
US8389720B2 (en)	2008-11-13	2013-03-05	Merck Sharp & Dohme Corp.	Quinolone neuropeptide S receptor antagonists

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE1467781A1 (de) *	1963-07-15	1968-12-05	Boehringer Sohn Ingelheim	Verfahren zur Herstellung von Dragees mit verlaengerter Wirkstofffreigabe
PT66201B (fr) *	1976-02-23	1978-11-07	Corvi Mora E	Procede et composition pour la therapeutique des maladies circulatoires cerebrales

1983
- 1983-10-24 LU LU85058A patent/LU85058A1/fr unknown
1984
- 1984-10-12 EP EP84201468A patent/EP0142877A3/de not_active Withdrawn

Also Published As

Publication number	Publication date
EP0142877A2 (de)	1985-05-29
EP0142877A3 (de)	1986-10-08

Publication	Publication Date	Title
LU85058A1 (fr)	1985-06-19	Comprimes pharmaceutiques a liberation prolongee,leur preparation et leur utilisation
CA2283133C (fr)	2006-07-25	Compositions pharmaceutiques pour la liberation controlee de substances actives
EP1524968B1 (de)	2007-12-26	Oral anzuwendendes arzneimittel bestehend aus einer vielzahl von mikrokapseln für die verzögerte verabreichung von wirkstoffen
EP1558220B1 (de)	2010-02-10	Orale zusammensetzungen zur behandlung von diabetes
US9937157B2 (en)	2018-04-10	Modified release dosage forms of xanthine oxidoreductase inhibitor or xanthine oxidase inhibitors
AU2002303897B2 (en)	2006-11-16	System for osmotic delivery of pharmaceutically active agents
EP1496869B1 (de)	2009-02-18	Beschichtete teilchen mit verzögerter freisetzung und diese enthaltende tabletten
EP2276474B1 (de)	2019-03-06	Feste orale multipartikelhaltige darreichungsform mit zweifachem freisetzungsprofil
JP2003513918A (ja)	2003-04-15	トルテロジン含有医薬組成物及びその使用
CA2589137A1 (fr)	2006-06-01	Medicament oral a liberation modifiee d'au moins un principe actif sous forme multimicrocapsulaire
JPS635020A (ja)	1988-01-11	制御放出性イブプロフエン製剤
JP4457003B2 (ja)	2010-04-28	放出制御医薬組成物
WO2021129735A1 (zh)	2021-07-01	一种固体制剂及其制备方法和用途
EP1435921A1 (de)	2004-07-14	Verwendung von ropinirol formuliert als mehrschichtige tablette mit kontrollierter wirkstoffabgabe zur herstellung eines medikaments zur behandlung von fibromyalgie
EP1118321A1 (de)	2001-07-25	Feste pharmazeutische Zusammensetzungen für die kontrollierte Freisetzung von aktiven Substanzen
FR2885526A1 (fr)	2006-11-17	Medicament oral a base d'inhibiteur de pompe a protons
EP1465607B1 (de)	2007-03-21	Pharmazeutische zusammensetzung mit modifizierter freisetzung
JP4945043B2 (ja)	2012-06-06	モルシドミンの放出時間延長を伴う経口投与用新規生薬製剤
WO2011144724A1 (en)	2011-11-24	A pharmaceutical controlled release composition of losartan
KR102173549B1 (ko)	2020-11-04	복합 생약재 추출물 함유 방출 조절 제제
CA2608911A1 (fr)	2006-11-30	Forme pharmaceutique orale a base d'au moins un principe actif dont la solubilite varie en fonction des conditions de ph gastrique
US20090123536A1 (en)	2009-05-14	Oral Pharmaceutical Form of Losartan
WO2023002004A1 (en)	2023-01-26	Multiparticulate pharmaceutical composition
FR2884145A1 (fr)	2006-10-13	Forme pharmaceutique orale de losartan